Click for stock quote
 






OVERVIEW
MANAGEMENT TEAM
BOARD OF DIRECTORS
NEWS RELEASES
DIRECTIONS TO MIGENIX
HOME » CORPORATE: BOARD OF DIRECTORS



BOARD OF DIRECTORS

 

Douglas Johnson, Chairman, Director

Mr. Johnson has over 30 years of experience in the financing of both public and private companies. Mr. Johnson has operated Canfund Ventures Corporation ("Canfund") since 1982 as chief executive officer and president. Canfund is a venture investor specializing in microcap and start-up companies and has extensive investments in resources and technology companies. Mr. Johnson is the president, chief executive officer and a director of Foundation Resources Inc., and is also a director of both Search Capital Inc. and Ridgeline Energy Services Inc., formerly Gavwest Resources Ltd., all of which are listed on the TSX Venture Exchange.

 

Paul Brennan, Chief Executive Officer, Director

Paul Brennan was appointed as the Company's Chief Executive Officer on October 20, 2009.  Since May 2009 Mr. Brennan has been a Principal at Pacific BioPartners, a consulting company focusing on supporting Biotech companies, including MIGENIX, with general management and business development expertise. From August 2008 to April 2009 Mr Brennan was the CEO and a Board Member of Altair Therapeutics an emerging biopharmaceutical company based in San Diego and focused on developing inhaled therapeutics for respiratory diseases. In January 2007, Mr Brennan joined Aspreva Pharmaceuticals as Senior Vice President, Business Development, and was involved in the sale of the company to the Galenica Corporation for $920 million. Between 2002 and 2007 Mr Brennan worked for AnorMED, and held various positions in Business Development, Marketing and General Management. Mr Brennan was a Board Member and was Acting-President of AnorMED when it was sold to the Genzyme Corporation for $590 million. Prior to joining AnorMED Mr Brennan worked for AstraZeneca in a number of management positions in Business Development and Regulatory Affairs based in Canada, Sweden and the UK. Mr Brennan has a M.Sc and B. Sc from Queen's University in Kingston.

 

Bruce Schmidt, President and Chief Financial Officer (Interim), Director

Bruce Schmidt was appointed as the Company's President and Chief Executive Officer (interim) in August 2008 and provides those services through his management company, RJS Management Ltd. Mr. Schmidt ceased to be the Company’s Chief Executive Officer effective October 20, 2009 with the appointment of Mr. Brennan. From 1993 to 2000, Mr. Schmidt was a founder and Chief Executive Officer of a University of British Columbia spin-off biotechnology company focused on novel compounds for the treatment of various cancers and neurological disorders. In 2000, Mr. Schmidt helped found Genome British Columbia, a life-sciences research institute with the objective of building world class genomics capabilities in Canada. Mr. Schmidt has also served as a director for a number of high-tech and biotech companies in Canada. Mr. Schmidt is currently a director of GreenAngel Energy Corp. and En2Go International Ltd.  Mr. Schmidt is a past-director of the Canadian Healthcare Licensing Association, past-Chair of the B.C. Nanotechnology Alliance and past-Chair of Life Sciences British Columbia (formerly BCBiotech).

 

Pieter Dorsman, Director

Pieter Dorsman is President and a Director of Redpeaks Management, Inc., a consulting firm in Vancouver, which advises companies on finance and investment, corporate development, legal structure and overall business strategies.  Through Redpeaks, Mr. Dorsman has taken on a number of financing and restructuring mandates for technology, media and life science companies.  He is a co-founder and former CFO of Actenum Corp. and currently an advisory board member and VP Corporate Development at Aftercad Software Inc. Other Redpeaks clients have included Chrysalix Energy and Ostara Nutrient Recovery Technologies.  Mr. Dorsman currently serves on the boards of ClearVision Technologies Inc. and MIGENIX Inc, a TSX-listed biotechnology firm.  Prior to establishing Redpeaks, Mr. Dorsman held a number of senior positions at UBS in Hong Kong where he was responsible for project and corporate finance mandates in the South-East Asian region as well as in China.  Prior to that he worked for Barclays Bank PLC in Hong Kong and London where he started his career. Mr. Dorsman holds a Master’s degree in Economic and Social History for the Erasmus Universiteit in Rotterdam, The Netherlands where he also studied law.

 

Alistair Duncan Jr., B.Sc., CA, Director

Alistair Duncan is President and CEO of Vancouver-based biotechnology company viDA Therapeutics Inc.  From 1998 to 2008 Mr. Duncan was President and CEO of Chromos Molecular Systems Inc., where he was also a founder and Director.  Prior to that, he was a Principal with the Ernst & Young Corporate Finance and International Life Sciences Group where he provided high technology and life sciences companies with corporate advisory services in strategic planning, valuations, financing, divestitures, and mergers & acquisitions.  Mr. Duncan holds a CA designation and a BSc in Biochemistry from the University of British Columbia.

 

Andrew Rae, Director

Mr. Rae is the chief executive officer and president of iCo Therapeutics Inc., an ocular development company he co-founded in 2005. Mr. Rae has spent a decade in the biotechnology industry, formerly as chief financial officer with Ability Biomedical Corporation. Mr. Rae has also served as vice president, Finance and Corporate Affairs at Active Pass Pharmaceuticals. Previously, Mr. Rae served as biotechnology equities analyst at Goepel Shields & Partners (now Raymond James Ltd.), covering Canadian biotechnology stocks.


[ TOP ]



© 1996 - 2010 MIGENIX Inc.
Privacy      Legal Disclaimer